Daniel P. Petrylak, MD | Authors


Cabazitaxel Improves rPFS in Patients with mCRPC

October 20, 2019

Daniel P. Petrylak, MD, discusses the efficacy results from the CARD trial, which evaluated the radiographic progression-free survival of cabazitaxel combined with either abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer.

Enfortumab Vedotin Appears Well-Tolerated and Active in Advanced Bladder Cancers

August 21, 2019

Daniel P. Petrylak, MD, discusses the data from the phase II EV-201 trial investigating enfortumab vedotin as treatment of patients with locally advanced or metastatic urothelial cancer previously treated with platinum-based chemotherapy or a PD-1/PD-L1 checkpoint inhibitor.

Combination Ramucirumab and Docetaxel for Urothelial Carcinoma

May 05, 2018

Daniel P. Petrylak, MD, a professor of Medicine and Urology and co-director of the Signal Transduction Research Program at Yale School of Medicine, discussed results from the phase III RANGE trial for the combination of ramucirumab (Cyramza) and docetaxel in patients with urothelial carcinoma.

Dr. Petrylak Discusses BCG for the Treatment of Patients With Non-Invasive Bladder Cancer

August 28, 2015

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and of Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, discusses bacillus calmette-guerin (BCG) therapy for the treatment of patients with non-invasive bladder cancer.